We are live on ! Find out more
EDIT icon

Editas Medicine

264 hedge funds and large institutions have $591M invested in Editas Medicine in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 75 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

27% more call options, than puts

Call options by funds: $23.8M | Put options by funds: $18.6M

5% more capital invested

Capital invested by funds: $561M → $591M (+$30.3M)

3% more funds holding

Funds holding: 256264 (+8)

1.05% more ownership

Funds ownership: 69.17%70.22% (+1%)

3% less repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 75

Holders
264
Holders Change
+8
Holders Change %
+3.13%
% of All Funds
4.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
39
Increased
73
Reduced
75
Closed
28
Calls
$23.8M
Puts
$18.6M
Net Calls
+$5.13M
Net Calls Change
+$6.09M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$85.5M +$4.03M +258,565 +4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$82.3M +$1.4M +89,730 +1%
State Street
3
State Street
Massachusetts
$77.7M -$23.9M -1,531,109 -19%
Millennium Management
4
Millennium Management
New York
$23M +$27M +1,731,710 +1,146%
PHS
5
PFM Health Sciences
California
$15.7M +$10.1M +649,370 +103%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$15.4M +$466K +29,890 +2%
JP Morgan Chase
7
JP Morgan Chase
New York
$14.2M -$581K -37,275 -3%
Goldman Sachs
8
Goldman Sachs
New York
$13.7M +$5.11M +328,003 +42%
Capital World Investors
9
Capital World Investors
California
$13.5M
Two Sigma Advisers
10
Two Sigma Advisers
New York
$13.2M +$1.56M +100,000 +10%
Two Sigma Investments
11
Two Sigma Investments
New York
$12.3M +$4.89M +313,759 +45%
CS
12
Credit Suisse
Switzerland
$12.2M -$782K -50,195 -5%
Morgan Stanley
13
Morgan Stanley
New York
$11.1M -$2.57M -164,717 -15%
Citadel Advisors
14
Citadel Advisors
Florida
$11M -$5.65M -362,299 -29%
Northern Trust
15
Northern Trust
Illinois
$9.49M +$1.9M +121,703 +19%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$8.04M -$601K -38,556 -6%
N
17
Nuveen
North Carolina
$7.15M -$33.5K -2,153 -0.4%
Charles Schwab
18
Charles Schwab
California
$6.11M +$197K +12,628 +3%
Capital Fund Management (CFM)
19
Capital Fund Management (CFM)
France
$6.06M +$1.81M +116,188 +31%
Bank of America
20
Bank of America
North Carolina
$5.62M +$2.55M +163,966 +56%
Rafferty Asset Management
21
Rafferty Asset Management
New York
$5.36M +$1.47M +94,662 +28%
Citigroup
22
Citigroup
New York
$5.24M -$944K -60,569 -12%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$4.78M +$2.05M +131,693 +51%
CSS
24
Cubist Systematic Strategies
Connecticut
$4.61M +$2.32M +148,984 +65%
Norges Bank
25
Norges Bank
Norway
$4.48M

EDIT Hedge Fund Activity: Q3 2022 in Review

264 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2022, worth a combined $591M — up 5.4% from $561M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new EDIT positions and 28 closed out — a net gain of 11 holders — while 73 added to existing stakes and 75 trimmed.

The largest buyer was Millennium Management, adding an estimated $27M. The largest seller was State Street, cutting an estimated $23.9M.

  • 264 institutional investors held Editas Medicine (EDIT) as of Q3 2022, up from 256 in Q2 2022.
  • Funds reported $591M of Editas Medicine stock for Q3 2022, up 5.4% quarter-over-quarter.
  • 39 funds opened new Editas Medicine positions in Q3 2022 and 28 closed out, a net change of +11 holders.
  • The largest Editas Medicine buyer in Q3 2022 was Millennium Management, an estimated $27M added.
  • The largest Editas Medicine seller in Q3 2022 was State Street, an estimated $23.9M sold.

Based on aggregated 13F filings for Q3 2022.